A direct functional test
Twenty-five people with chronic kidney disease participated in a randomized, blinded crossover trial of NR, coenzyme Q10 and placebo, each for six weeks. The primary outcomes were peak oxygen consumption and work efficiency during cycle testing. Neither active intervention significantly improved those outcomes compared with placebo. [1]
NR changed several metabolic and lipid measurements and reduced oxygen consumption at one submaximal workload. Estimated kidney filtration did not change significantly. The paper therefore reports biochemical effects and a limited submaximal observation without a demonstrated improvement in peak exercise capacity or total work efficiency. [1]
Peak and submaximal results should not be merged
An exercise test can produce several measurements at different workloads. A change at one stage does not automatically mean that the person achieved a higher peak or completed more work. The endpoint’s position in the test is part of its meaning.
A product claiming improved endurance should identify which functional result supports that claim. If the cited paper’s primary exercise outcome was negative, a selected secondary measurement should not be used to conceal it. The appropriate summary can acknowledge both findings without making them equivalent.
The same applies to the metabolic data. A change in a pathway associated with energy production may help explain biology. It does not erase a direct test showing no significant improvement in the main functional outcome.
These were separate interventions in a clinical population
The study compared NR, coenzyme Q10 and placebo periods. It should not be described as proof that a combined NR-CoQ10 retail blend improves exercise. A combination requires evidence for that combination, not a rearrangement of the study title.
The participants also had chronic kidney disease. Their clinical context differs from healthy athletes, and the trial does not provide a general sports-performance recommendation. Questions about supplement suitability belong with the clinician responsible for the person’s kidney care.
For a different kidney setting, read the acute kidney-injury safety study. Acute and chronic disease, brief safety observation and functional testing are distinct research questions. A shared organ label is not enough to combine their conclusions.
This trial is useful precisely because it included a performance assessment. It asks whether the proposed metabolic rationale translated into a directly measured task. The result was mixed, with no significant primary exercise benefit. Our biomarker guide explains why that clinical boundary matters when a product uses mitochondrial language to promise better stamina. Keep the tested task and the participant group beside the claim before treating the citation as applicable to you. A mechanistic rationale is a starting point for that comparison.